Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
NERV Minerva Neurosciences Inc
- Stocks
- Healthcare
- NASDAQ: NERV
Price (delayed)
$1.8
Market cap
$12.59M
P/E Ratio
2.2
Dividend/share
N/A
EPS
$0.82
Enterprise value
$55.2M
Minerva's portfolio of compounds includes: roluperidone (MIN-101), in clinical development for schizophrenia, and MIN-301, in pre-clinical development for Parkinson's disease.
Highlights
The company's net income has surged by 120% YoY
The EPS has surged by 118% year-on-year
The company's quick ratio fell by 28% YoY but it rose by 18% QoQ
Minerva Neurosciences's equity has increased by 20% YoY but it has decreased by 13% QoQ
Key stats
What are the main financial stats of NERV
Market
Valuations
Earnings
Shares outstanding
6.99M
Market cap
$12.59M
Enterprise value
$55.2M
Price to earnings (P/E)
2.2
Price to book (P/B)
N/A
Price to sales (P/S)
N/A
EV/EBIT
8.83
EV/EBITDA
8.8
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$19.07M
Net income
$6.25M
EBIT
$6.25M
EBITDA
$6.27M
Free cash flow
-$17.53M
Per share
Balance sheet
Liquidity
EPS
$0.82
EPS diluted
$0.82
Free cash flow per share
-$2.32
Book value per share
-$4.17
Revenue per share
$0
TBVPS
$2.37
Total assets
$32.8M
Total liabilities
$61.95M
Debt
$60M
Equity
-$29.15M
Working capital
$15.98M
Debt to equity
-2.06
Current ratio
9.21
Quick ratio
8.93
Net debt/EBITDA
6.79
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
15.7%
Return on equity
N/A
Return on invested capital
9.8%
Return on capital employed
20.3%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
NERV stock price
How has the Minerva Neurosciences stock price performed over time
Intraday
0.84%
1 week
-2.17%
1 month
10.43%
1 year
-45.62%
YTD
-18.98%
QTD
5.88%
Financial performance
How have Minerva Neurosciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$19.07M
Net income
$6.25M
Gross margin
N/A
Net margin
N/A
The company's net income has surged by 120% YoY
NERV's operating income is up by 22% year-on-year and by 13% since the previous quarter
Price vs fundamentals
How does NERV's price correlate with its fundamentals
Growth
What is Minerva Neurosciences's growth rate over time
Valuation
What is Minerva Neurosciences stock price valuation
P/E
2.2
P/B
N/A
P/S
N/A
EV/EBIT
8.83
EV/EBITDA
8.8
EV/Sales
N/A
The EPS has surged by 118% year-on-year
Minerva Neurosciences's equity has increased by 20% YoY but it has decreased by 13% QoQ
Efficiency
How efficient is Minerva Neurosciences business performance
Minerva Neurosciences's return on assets has surged by 130% YoY
The return on invested capital has surged by 125% year-on-year
Dividends
What is NERV's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for NERV.
Financial health
How did Minerva Neurosciences financials performed over time
The total assets is 47% less than the total liabilities
The total assets has contracted by 35% YoY and by 12% from the previous quarter
Minerva Neurosciences's total liabilities has decreased by 29% YoY
The debt has contracted by 29% YoY
Minerva Neurosciences's equity has increased by 20% YoY but it has decreased by 13% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.